Immunomic TherapeuticsImmunomic Therapeutics
Immunomic TherapeuticsImmunomic Therapeutics
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us

Media

  • Highlights
  • Press Releases
  • Events
  • News
  • Articles
  • Posters
  • Immunomic Sr. Vice President to Speak at Skin Vaccination Summit 2017 in the Netherlands

    Highlights Press Releases
    May 22, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will present on DNA vaccines
    Read more
  • Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)

    Highlights Press Releases
    Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)   Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational
    Read more
  • Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™

    Featured Highlights Press Releases
    Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™   May 18, 2017 Eastern Standard Time ROCKVILLE, Md. & SAN FRANCISCO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held,
    Read more
  • Immunomic Therapeutics Aims to Advance Research for Glioblastoma

    Blog
    May is Brain Cancer Awareness Month and Rockville, MD based Immunomic is dedicated to raising awareness and advancing research for this devastating cancer. The facts are grim, over 700,000 Americans
    Read more
  • Immunomic Licenses CMV-Targeting Tech from Annias for LAMP-Vax Cancer Vaccines

    Articles
    May 15, 2017 Immunomic Licenses CMV-Targeting Tech from Annias for LAMP-Vax Cancer Vaccines Immunomic Therapeutics negotiated an exclusive license to Annias Immunotherapeutics’ platform covering technology for targeting cytomegalovirus (CMV) antigens
    Read more
  • Immunomic Therapeutics Raises Awareness for Asthma and Allergy

    Blog
    This month, we are celebrating Allergy and Asthma Awareness Month. May is peak season for allergy and asthma sufferers and we want to help raise awareness about the dangers of
    Read more
  • Immunomic Therapeutics Announces Winner of Cancer Discovery Incubator Award

    Blog
    Midissia Therapeutics to Develop Immune Intensification Technology at Immunomic Labs Last night, Immunomic Therapeutics announced the winner of their Cancer Discovery Incubator Award: Midissia Therapeutics (Midissia). Midissia is a clinical
    Read more
  • The Importance of National Infant Immunization Week

    Blog
    The Importance of National Infant Immunization Week Looking for some good news today? Check out the infant immunization milestones we’ve reached through science: We can now protect infants and children
    Read more
  • Immunomic Therapeutics Celebrates World Immunization Week

    Blog
    Immunomic Therapeutics Celebrates World Immunization Week This week, we are celebrating World Immunization Week to raise awareness about the importance of following immunization schedules throughout life because when immunization rates
    Read more
  • Here’s the visual proof of why vaccines do more good than harm

    Blog
    Here’s the visual proof of why vaccines do more good than harm By Jia You Apr. 27, 2017, 1:15 PM Vaccines have beat back infectious diseases. Bubbles represent reported U.S.
    Read more
  • Two Major Macro Trends: The Rise of China-based Biotech Companies and Large Pharma’s Continued Sourcing of New Discoveries

    Blog
    A recent Wall Street Journal article addressed the intersection of two major macro trends within the biotech industry: the rise of China-based innovation-driven biotech companies and the continued sourcing of
    Read more
  • The Role of CD4+ T helper Cells in Cancer

    Blog
    A new consensus has emerged on the CD4+ helper T cell and its role in facilitating and mediating sustained anti-tumor responses. The importance of this cell population has emerged, in
    Read more
1234567891011121314151617181920212223242526
← Previous pageNext page →

Content
  • Pipeline
  • Partnerships
  • Team
  • Media
  • Contact Us
Careers
  • Careers
  • Compensation & Benefits
  • Culture & Beliefs
Policies
  • Expanded Access Policy
  • Privacy Policy
Social
  • Facebook
  • X / Twitter
  • Youtube
Telephone

+1.301.968.3501

Address

15010 Broschart Road

Rockville, MD 20850

© 2020 Immunomic Therapeutics, Inc. All Rights Reserved.